Literature DB >> 9060605

Risk groups of myeloma patients by histologic pattern and proliferative activity.

A Pich1, L Chiusa, F Marmont, R Navone.   

Abstract

We investigated the histologic pattern and the cell proliferative activity of myeloma cells by the analysis of the nucleolar organizer regions (AgNORs) in bone marrow biopsy specimens from 150 multiple myelomas at diagnosis. The objective was an attempt to define risk groups of myeloma patients. On univariate analysis, the percentage of bone marrow plasma cells (BMPC%), the pattern of infiltration, the degree of plasma cell (PC) atypia, the marrow fibrosis, and the number of AgNOR/PC were correlated with survival time. On multivariate analysis, only AgNOR counts and pattern of infiltration retained independent prognostic significance. At 4-year followup, all patients with BMPC% < or = 20, interstitial pattern of invasion, and well-differentiated (G1) PC plus AgNOR/cell < or = 3.32 were alive, while no patient with BMPC% >50, diffuse pattern of infiltration, and poorly differentiated (G3) PC plus AgNOR/cell >5.15 survived (p < 0.0001). In conclusion, the histologic pattern and proliferative activity of myeloma cells, evaluated by AgNOR counts, are reliable predictors of survival in myeloma. Both parameters can be easily assessed in the same biopsy specimen, are reproducible, and permit identification of a group of patients with favourable outcome at 4-year followup. Thus, bone marrow biopsy should always be included in the diagnostic procedures for myeloma patients.

Entities:  

Mesh:

Year:  1997        PMID: 9060605     DOI: 10.1097/00000478-199703000-00011

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  4 in total

1.  Evaluation of argyrophilic nucleolar organiser regions (AgNORs) in multiple myeloma.

Authors:  S I Papadhimitriou; D Daskalopoulou; P Tsaftaridis; S Markidou; M Stamatelou
Journal:  J Clin Pathol       Date:  2000-06       Impact factor: 3.411

2.  Proliferation and Angiogenesis Using Immunohistochemistry in Prognosticating Multiple Myeloma.

Authors:  Sarah Grace Priyadarshini; Debdatta Basu; Rakhee Kar; T K Dutta
Journal:  Indian J Hematol Blood Transfus       Date:  2016-01-19       Impact factor: 0.900

3.  Pancytopenia in Multiple Myeloma- An Enigma: Our Experience from Tertiary Care Hospital.

Authors:  Hanaganahalli B Sridevi; Sharada Rai; Pooja K Suresh; Meludurgamutt S Somesh; Jessica Minal
Journal:  J Clin Diagn Res       Date:  2015-11-01

4.  The impact of bone marrow fibrosis and JAK2 expression on clinical outcomes in patients with newly diagnosed multiple myeloma treated with immunomodulatory agents and/or proteasome inhibitors.

Authors:  Barry Paul; Yue Zhao; Gavin Loitsch; Daniel Feinberg; Parker Mathews; Ian Barak; Megan Dupuis; Zhiguo Li; Lindsay Rein; Endi Wang; Yubin Kang
Journal:  Cancer Med       Date:  2020-07-06       Impact factor: 4.452

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.